Citation
Kopp, Jeffrey B., et al. "APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-associated Nephropathy." Journal of the American Society of Nephrology : JASN, vol. 22, no. 11, 2011, pp. 2129-37.
Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22(11):2129-37.
Kopp, J. B., Nelson, G. W., Sampath, K., Johnson, R. C., Genovese, G., An, P., Friedman, D., Briggs, W., Dart, R., Korbet, S., Mokrzycki, M. H., Kimmel, P. L., Limou, S., Ahuja, T. S., Berns, J. S., Fryc, J., Simon, E. E., Smith, M. C., Trachtman, H., ... Winkler, C. A. (2011). APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. Journal of the American Society of Nephrology : JASN, 22(11), 2129-37. https://doi.org/10.1681/ASN.2011040388
Kopp JB, et al. APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-associated Nephropathy. J Am Soc Nephrol. 2011;22(11):2129-37. PubMed PMID: 21997394.
TY - JOUR
T1 - APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.
AU - Kopp,Jeffrey B,
AU - Nelson,George W,
AU - Sampath,Karmini,
AU - Johnson,Randall C,
AU - Genovese,Giulio,
AU - An,Ping,
AU - Friedman,David,
AU - Briggs,William,
AU - Dart,Richard,
AU - Korbet,Stephen,
AU - Mokrzycki,Michele H,
AU - Kimmel,Paul L,
AU - Limou,Sophie,
AU - Ahuja,Tejinder S,
AU - Berns,Jeffrey S,
AU - Fryc,Justyna,
AU - Simon,Eric E,
AU - Smith,Michael C,
AU - Trachtman,Howard,
AU - Michel,Donna M,
AU - Schelling,Jeffrey R,
AU - Vlahov,David,
AU - Pollak,Martin,
AU - Winkler,Cheryl A,
Y1 - 2011/10/13/
PY - 2011/10/15/entrez
PY - 2011/10/15/pubmed
PY - 2011/12/22/medline
SP - 2129
EP - 37
JF - Journal of the American Society of Nephrology : JASN
JO - J Am Soc Nephrol
VL - 22
IS - 11
N2 - Trypanolytic variants in APOL1, which encodes apolipoprotein L1, associate with kidney disease in African Americans, but whether APOL1-associated glomerular disease has a distinct clinical phenotype is unknown. Here we determined APOL1 genotypes for 271 African American cases, 168 European American cases, and 939 control subjects. In a recessive model, APOL1 variants conferred seventeenfold higher odds (95% CI 11 to 26) for focal segmental glomerulosclerosis (FSGS) and twenty-nine-fold higher odds (95% CI 13 to 68) for HIV-associated nephropathy (HIVAN). FSGS associated with two APOL1 risk alleles associated with earlier age of onset (P = 0.01) and faster progression to ESRD (P < 0.01) but similar sensitivity to steroids compared with other subjects. Individuals with two APOL1 risk alleles have an estimated 4% lifetime risk for developing FSGS, and untreated HIV-infected individuals have a 50% risk for developing HIVAN. The effect of carrying two APOL1 risk alleles explains 18% of FSGS and 35% of HIVAN; alternatively, eliminating this effect would reduce FSGS and HIVAN by 67%. A survey of world populations indicated that the APOL1 kidney risk alleles are present only on African chromosomes. In summary, African Americans carrying two APOL1 risk alleles have a greatly increased risk for glomerular disease, and APOL1-associated FSGS occurs earlier and progresses to ESRD more rapidly. These data add to the evidence base required to determine whether genetic testing for APOL1 has a use in clinical practice.
SN - 1533-3450
UR - https://www.unboundmedicine.com/medline/citation/21997394/full_citation
L2 - https://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=21997394
DB - PRIME
DP - Unbound Medicine
ER -